Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir

Clinical Transplantation

Volumn 18, Issue 2, 2004, Pages 179-185

  Palmer, Scott M ^a   Grinnan, Dan C ^a   Reams, B Diane ^a   Steele, Mark P ^a   Messier, Robert H ^a   Davis, R Duane ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Lung transplantation; Prophylaxis

Indexed keywords

GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HYPERIMMUNE GLOBULIN;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; KAPLAN MEIER METHOD; LEUKOPENIA; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; SAMPLE SIZE; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LUNG TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS;

EID: 1642524467     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-0012.2003.00152.x     Document Type: Article

References (22)

1. Duncan AJ, Dummer JS, Paradis IL et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991: 10: 638.
2. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999: 67: 315.
3. Gutierrez CA, Chaparro C, Krajden M, Winton T, Kesten S. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998: 113: 924.
4. Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993: 67: 5360.
5. Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest 1999: 116: 1265.
6. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996: 15: 881.
7. Duncan SR, Grgurich WF, Iacono AT et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994: 150.
8. Palmer SM, Lawrence CM, Kanj SS, Davis RD, Tapson VF. Cytomegalovirus associated infections in lung transplant recipients. Am J Respir Crit Care Med 1997: 155: A274.
9. Hertz MI, Jordan C, Savik SK et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998: 17: 913.
10. Nankivell BJ, Malouf MA, Russ GR et al. Maintenance therapy with oral ganciclovir after treatment of cytomegalovirus infection. Clin Transplant 1998: 12: 270.
11. Snell GI, Kotsimbos TC, Levvey BJ et al. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. J Antimicrob Chemother 2000: 45: 511.
12. Lau CL, Palmer SM. D'Amico TA, Harpole DH, Tapson VF, Davis RD. Lung transplantation at Duke University Medical Center. In: Cecka JM, Teraski PI eds. Clinical Transplants 1998. Los Angeles: Tissue Typing Laboratory, 1998: 327.
13. Berry GJ, Brunt EM, Chamberlain D et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990: 9: 593.
14. Cooper JD, Billingram M, Egan T et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993: 12: 713.
15. Ettinger NA, Bailey TC, TrulocK EP et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993: 147: 1017.
16. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: A systematic review of recent publications. J Heart Lung Transplant 2002: 21: 271.
17. Valantine HA, Luikart H, Doyle R et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: A comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001: 72: 1647.
18. Spector SA, McKinley GF, Lalezari JP et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996: 334: 1491.
19. Jung C, Englemann E, Borner K, Oermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001: 33: 3621.
20. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000: 356: 645.
21. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002: 185: 20.
22. Curran M, Noble S. Valganciclovir. Drugs 2001: 61: 1145.